Sign In
Buy ARQT
$21.35
+0.560 (+2.69%)
At Close: Jun 03, 2026
Arcutis to Present at Upcoming Investor Conferences
04:00pm, Tuesday, 19'th Aug 2025
WESTLAKE VILLAGE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know
10:56am, Thursday, 14'th Aug 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 44.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is question
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
10:41am, Monday, 11'th Aug 2025
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Tenet Healthcare (THC) have performed compared to their sector so far this year.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 08'th Aug 2025
WESTLAKE VILLAGE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2025 Earnings Call Transcript
02:53am, Thursday, 07'th Aug 2025
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Frank Watanabe - Corporate Participant Latha Vairavan - Corporate Participa
Arcutis (ARQT) Q2 Revenue Soars 164%
12:07am, Thursday, 07'th Aug 2025
Arcutis (ARQT) Q2 Revenue Soars 164%
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates
06:11pm, Wednesday, 06'th Aug 2025
Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.42 per share a year ago.
Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update
04:00pm, Wednesday, 06'th Aug 2025
Q2 2025 net product revenue for ZORYVE® (roflumilast) was $81.5 million, a 164% increase compared to Q2 of 2024, and a 28% increase compared to Q1 of 2025, driven by strong portfolio demand growth ZO
Arcutis: Leveraging Zoryve's Success While Positioning For Pipeline Expansion
03:54pm, Friday, 01'st Aug 2025
Upgrading Arcutis Biotherapeutics, Inc. from Hold to Buy due to Zoryve's strong regulatory and commercial momentum, with revenue and prescription growth exceeding expectations. Zoryve's expanding labe
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:07am, Wednesday, 30'th Jul 2025
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
04:00pm, Wednesday, 23'rd Jul 2025
Arcutis announced today that it will report Q2 2025 financial results and provide a business update on Aug 6, 2025 after the U.S. financial markets close.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Thursday, 03'rd Jul 2025
WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction
11:25pm, Friday, 27'th Jun 2025
Arcutis Biotherapeutics' ZORYVE (roflumilast) offers superior efficacy and safety over current topical treatments for mild-to-moderate atopic dermatitis. The atopic dermatitis market is large and shif
The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD) Recommendation
Arcutis Biotherapeutics: Another Approval Under Their Belt
04:43am, Wednesday, 25'th Jun 2025
Shares of Arcutis Biotherapeutics have fallen by 5% since my March update. Zoryve's 4th approval in scalp & body psoriasis should further boost sales and contribute to the "portfolio effect". IP devel
